Home » Teva’s Austedo XR Approved for Tardive Dyskinesia and Huntington’s Disease-Associated Chorea
Teva’s Austedo XR Approved for Tardive Dyskinesia and Huntington’s Disease-Associated Chorea
Teva Pharmaceuticals has received FDA approval for its Austedo XR (deutetrabenazine) extended-release tablets for adults with tardive dyskinesia and chorea associated with Huntington’s disease.
The extended-release version of the drug for once-daily use has demonstrated therapeutic equivalence to the twice-daily Austedo formulation.
For some patients living with the conditions “treatment adherence can be a challenge that this new once-daily dosing option can help to address,” the company said.
Teva plans to launch Austedo XR in the U.S. later this year.
Upcoming Events
-
18Jul
-
21Oct